ClinicalTrials.gg
Active, not recruitingNCT04838418TOMCATUpdated Apr 9, 2026

Transorbital Ultrasound and Other Markers for Prognosis Prediction After Cardiac Arrest

An observational study in Cardiac Arrest, sponsored by University Hospital Pilsen. Active, not recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by University Hospital Pilsen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Heart Arrest with a site in Czechia — 7 open to participants now, 8 under way, none of them phase 3. Heart Arrest · Czechia.

Started
2021
the only one that year
Observational
7 of 15
3 open now
Registered
7th of 15
by date
Lead sponsor
2 of 15
University Hospital Pilsen

Among the 15 studies in Heart Arrest with a site in Czechia, this one is the only one that started in 2021, is one of 7 observational ones, and was the 7th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

7 of the 15 studies in Heart Arrest with a site in Czechia are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Arrest with a site in Czechia, or all of them as a file.
02

Study summary

In sudden cardiac arrest patients with return of spontaneous circulation, brain damage is one of the main determinants of short-term mortality and poor prognosis (CPC 3-5). It is important to properly select group of patients in whom treatment is futile. According to current guidelines, multimodal approach is recommended. Optic nerve sheath diameter measured by ultrasound is non-invasive, fast, low-cost and readily available bed-side method, but evidence for its use as neuroprognostication modality is limited to only few small studies. The aim of this study is to evaluate validity of ONSD as neuroprognostication method at larger cohort of patients, compare it with other established methods and compare ultrasound and CT measurement of ONSD.

Read the detailed description

Additional relevant MeSH terms:

cardiac arrest, cardiovascular diseases, optic nerve sheath diameter.

03

Conditions studied

  • Cardiac Arrest

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male and female patients after cardiac arrest with subsequent ROSC, 18 years of age and older

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age of 18 years or older
  • out of hospital cardiac arrest of non-traumatic cause with CPR and subsequent ROSC
  • Glasgow coma scale (GCS) ≤ 7 or sedation 30 minutes after ROSC achievment

Exclusion criteria

Exclusion Criteria:

  • unavailable first measurment of the optic nerve sheath diameter (ONSD) measured by transorbital ultrasonography 24±6 hours after ROSC achievement
  • cardiac arrest
  • craniocerebral injury
  • intracranial tumor
  • active intracranial bleeding
  • haemorrhagic stroke and/or subarachnoid haemorrhage in the last 3 months
  • facial trauma affecting the eye area
  • active neuroendocrine tumor, small cell lung cancer, non-small cell lung
  • CPC 3-5 before cardiac arrest
  • sclerosis multiplex and/or optic neuritis of other etiology
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • ProcedureOptic nerve sheath diameter measured by transorbital ultrasound

    Optic nerve sheath diameter measured 3 mm behind eyeball. For every eyeball 2 measurements in axial and 2 measurements in sagital projections are performed. Summary value for every eyeball is arithmetic mean from these 4 measurements.

06

What researchers measure

Primary outcomes

  1. Value of ONSD for short-term neurological outcome prediction

    Assessment of the correlation between the optic nerve sheath diameter measured by transorbital ultrasonography and neurological outcome of patients (quantified by the CPC scale) after out of hospital cardiac arrest with subsequent ROSC

    Time frame: 30 days

  2. Value of ONSD for short-term mortality prediction

    Assessment of the correlation between optic nerve sheath diameter measured by transorbital ultrasonography and mortality during a 30-day follow-up.

    Time frame: 30 days

Secondary outcomes

  1. Comparison of ONSD and electrophysiologic modalities for neurological outcome prediction

    Assessment of the correlation between the optic nerve sheath diameter measured by transorbital ultrasonography and negative prognostic markers obtained by somatosensory evoked potentials examination and EEG in patients remaining in a coma even after the end of therapeutic hypothermia and sedation.

    Time frame: 96 hours

  2. Comparison of ONSD measurements by ultrasonography and computed tomography

    Assessment of accuracy of the optic nerve sheath diameter measured by ultrasonography compared to CT measurement performed 48 ± 12 hours after achievment of ROSC.

    Time frame: 48 hours

  3. Correlation between ONSD and fundoscopic signs of papillary edema

    Assessment of the correlation between the optic nerve sheath diameter measured by transorbital ultrasonography and grade of optic nerve papillary edema quantified by the Frisen scale on fundoscopic examination performed 48 ± 12 hours after achievment of ROSC.

    Time frame: 48 hours

  4. Correlation between ONSD and thickness of retinal nerve fibers measured by OCT

    Assessment of the correlation between the optic nerve sheath diameter measured by transorbital ultrasonography and thickness of retinal nerve fibers measured by optical coherence tomography at time intervals of 1, 3 and 5 months after achievment of ROSC.

    Time frame: 5 months

  5. Effect of blood carbon dioxide on ONSD

    Assessment of the correlation between the optic nerve sheath diameter measured by transorbital ultrasonography and paCO2 and ETCO2 values at the time of measurement.

    Time frame: 72 hours

  6. Value of ONSD for long-term neurological outcome and mortality

    Assessment of the correlation between the optic nerve sheath diameter measured by transorbital ultrasonography and mortality and neurological outcome of patients (quantified by the CPC scale) at 6 months after ROSC.

    Time frame: 6 months

  7. Correlation between blood NSE, copeptin and selected RNAs

    Assessment of the correlation between blood NSE, copeptin and selected micro-RNAs measured at defined time intervals from ROSC, to neurological outcome prediction in patients after out of hospital cardiac arrest with subsequent ROSC.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 70 months is above that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 9, 2021
StartActual
Jan 4, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04838418
Lead sponsor
University Hospital Pilsen
Collaborators
Na Homolce Hospital
Responsible party
Sponsor
First posted
Apr 9, 2021
Start date
Jan 4, 2021
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 9, 2026

Study contacts

Štefan Volovár, MUDr.
principal investigator · University hospital Plzen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion